NCT03728335 2026-03-13Enasidenib (AG-221) Maintenance Post Allogeneic HCT in Patients With IDH2 MutationCity of Hope Medical CenterPhase 2 Recruiting35 enrolled
NCT03683433 2026-03-05Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene MutationM.D. Anderson Cancer CenterPhase 2 Recruiting50 enrolled